BiotechTube
Renerva

Renerva

Pittsburgh, United States· Est.
renerva.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6.5M

Overview

Renerva is a private, preclinical-stage medical device company focused on transformative solutions for peripheral nerve repair. Its lead investigational device, the PNM-CAP™, has received FDA IDE approval to commence a first-in-human clinical trial, marking a significant milestone. The company operates with a lean, mission-driven team from its headquarters in Pittsburgh, PA, and is backed by experienced leadership in medtech, bioengineering, and clinical nerve surgery. Renerva aims to address the significant unmet need in treating nerve injuries, which often lead to chronic pain and loss of function.

Peripheral Nerve InjuryNeurosurgeryPlastic & Reconstructive Surgery

Technology Platform

Platform for developing implantable surgical devices, likely based on biomaterial scaffolds or decellularized matrices, designed to create an optimized microenvironment for peripheral nerve regeneration and repair.

Funding History

2
Total raised:$6.5M
Seed$4M
Grant$2.5M

Opportunities

The significant unmet medical need in peripheral nerve repair, where current options like autografts have major limitations, presents a large and growing market opportunity.
Successful clinical validation of PNM-CAP™ could position it as a new standard of care for bridging nerve gaps, offering a simpler, off-the-shelf solution.
The company's strong academic and clinical partnerships provide a foundation for continued innovation and credibility.

Risk Factors

The company faces high clinical risk as its entire value depends on unproven results from its first-in-human trial.
As a pre-revenue, single-asset company, it is vulnerable to financing risks and potential delays or failures in the complex FDA regulatory pathway for medical devices.
It also operates in a competitive landscape with other firms developing advanced nerve repair technologies.

Competitive Landscape

The peripheral nerve repair market includes established options like autografts (gold standard), processed nerve allografts (e.g., AxoGen's Avance®), and synthetic conduits. Competitors include both large medtech companies and smaller innovators focused on enhancing regeneration with growth factors, stem cells, or advanced biomaterials. Renerva's differentiation will need to be proven through clinical data demonstrating superior functional recovery for specific injury types.

More companies in Regenerative Medicine →More companies in United States →